Publications by authors named "K Ido"
Background: There are limited data on the efficacy of smartphone-based personal health records (PHRs) in patients with cardiovascular disease. This study aimed to examine the processes, outcomes and challenges associated with the implementation of integrated PHRs in patients with heart failure (HF) or coronary artery disease (CAD).
Methods: This prospective single-group study evaluated the effects of a PHR system with the capability to capture electronic health records and vital signs in patients with HF or CAD.
Article Synopsis
- Thromboembolism is a critical concern in patients undergoing endovascular treatment for ruptured cerebral aneurysms, and administering antiplatelet agents like aspirin before the procedure may lower this risk.
- The study, called ASTOP, is a multicenter, randomized, double-blind trial involving 484 patients, comparing the effects of 200 mg of aspirin versus a placebo prior to treatment.
- Primary outcomes will focus on measuring thromboembolic complications and ischemic lesions during the procedure, while secondary outcomes will assess cerebral ischemic events, bleeding incidents, and patient functional status after 90 days.
Article Synopsis
- Acute lymphoblastic leukemia (ALL) has poor outcomes when it relapses after stem cell transplants, but blinatumomab, a new treatment, shows promise, especially for advanced B-cell ALL.
- The case study highlights a 56-year-old woman who achieved a third complete remission (CR) with two cycles of blinatumomab after developing isolated extramedullary relapse (EMR) post-transplant.
- The patient remained free of complications and experienced a confirmed 2-year treatment-free remission, suggesting that blinatumomab is an effective option for treating EMR of B-ALL after allo-HCT due to its association with lower tumor burdens.
Article Synopsis
- Traditional relapse prediction models for post-transplant patients don't adapt based on new information collected after the transplant, making them less effective for treatment adjustments.
- This study focused on creating a dynamic relapse prediction model specifically for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients after allogeneic hematopoietic cell transplantation (allo-HCT), utilizing WT1mRNA levels from blood tests.
- The new model demonstrated significantly better predictive performance compared to older models, allowing for real-time predictions of relapse risk and is accessible through a user-friendly web application.
Article Synopsis
- * A study examined immune cell types and immunoglobulin levels in 39 patients who survived more than a year post-transplant, revealing significant differences based on the type of GVHD prophylaxis used.
- * Results indicated that patients receiving posttransplantation cyclophosphamide (PTCy) had better B-cell recovery and higher serum IgG levels compared to those treated conventionally, suggesting PTCy could help mitigate cGVHD.